跳至主要内容
临床试验/NCT00566423
NCT00566423已完成不适用

Biomarkers in the Diagnosis and Assessment of PAH

Northwell Health2 个研究点 分布在 1 个国家目标入组 75 人开始时间: 2007年5月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
75
试验地点
2
主要终点
Assess the correlation of plasma/arterial BNP and MIF levels pre/post with the 6 Minute walk test distance and echocardiographic parameters as surrogate markers of severity of PAH.

研究概览

简要总结

The investigators hypothesize that baseline plasma brain natriuretic peptide (BNP) and migration inhibitory factor (MIF) levels are surrogate markers of clinical severity of PAH and that changes in plasma brain natriuretic peptide (BNP) and MIF levels pre and post exercise.

详细描述

As above

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Confirmed diagnosis of PAH, based on currently accepted gold standard for Right Heart Catheterization.
  • Patients with mean artery pressure of greater that 25 mm Hg at rest or 30mm Hg during exercise with pulmonary capillary wedge pressure less than 18mm Hg on right heart catheterization.

排除标准

  • Significant left heart disease or renal insufficiency (serum creatinine > 1.5 mg%).

结局指标

主要结局

Assess the correlation of plasma/arterial BNP and MIF levels pre/post with the 6 Minute walk test distance and echocardiographic parameters as surrogate markers of severity of PAH.

时间窗: 2 year

次要结局

  • To determine if changes in plasma/arterial MIF levels pre/post 6MW test are due to MIF released from the lungs(2 year)

研究者

申办方类型
Other

研究点 (2)

Loading locations...

相似试验